Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives $11.90 Average Target Price from Analysts

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have earned an average rating of “Hold” from the fourteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.90.

Several research firms recently commented on IOVA. Zacks Research upgraded shares of Iovance Biotherapeutics to a “hold” rating in a research note on Tuesday, August 12th. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Iovance Biotherapeutics in a research note on Tuesday, August 19th. UBS Group downgraded shares of Iovance Biotherapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $17.00 to $2.00 in a research note on Friday, May 16th. Chardan Capital decreased their price target on shares of Iovance Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Wells Fargo & Company decreased their price target on shares of Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. WealthTrust Axiom LLC lifted its position in Iovance Biotherapeutics by 80.0% during the second quarter. WealthTrust Axiom LLC now owns 18,000 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 8,000 shares during the period. Accredited Investors Inc. bought a new stake in Iovance Biotherapeutics during the first quarter worth about $33,000. Diversify Wealth Management LLC bought a new stake in Iovance Biotherapeutics during the second quarter worth about $34,000. Flputnam Investment Management Co. bought a new position in shares of Iovance Biotherapeutics in the first quarter worth about $37,000. Finally, Blueshift Asset Management LLC bought a new position in shares of Iovance Biotherapeutics in the second quarter worth about $38,000. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $2.42 on Tuesday. Iovance Biotherapeutics has a one year low of $1.64 and a one year high of $12.51. The company has a market cap of $875.68 million, a P/E ratio of -1.97 and a beta of 0.82. The firm’s fifty day moving average price is $2.43 and its two-hundred day moving average price is $2.70.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. The company had revenue of $59.95 million during the quarter, compared to analyst estimates of $67.14 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Iovance Biotherapeutics will post -1.24 earnings per share for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.